Meir Bialer

List of Publications by Year in Descending Order

184 papers	6,441 citations	42 h-index	73 g-index
192 ext. papers	7,182 ext. citations	5.3 avg, IF	6.13 L-index

#	Paper	IF	Citations
184	Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?. *CNS Drugs*, **2022**, 36, 113	6.7	1
183	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. *Neuropharmacology*, **2021**, 185, 108442	5.5	18
182	Synthesis and Enantioselective Pharmacokinetic/Pharmacodynamic Analysis of New CNS-Active Sulfamoylphenyl Carbamate Derivatives. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
181	Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. *Pharmacology & Therapeutics*, **2021**, 226, 107866	13.9	4
180	Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. *Epilepsia*, **2021**, 62, 285-302	6.4	1
179	Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. *Epilepsia*, **2020**, 61, 1082-1089	6.4	28
178	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. *CNS Drugs*, **2020**, 34, 795-800	6.7	29
177	A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond. *Epilepsia*, **2020**, 61, 1543-1552	6.4	10
176	Response: Cannabidiol antiseizure activity and its interactions with clobazam: "It dJvu all over again" Yogi Berra. *Epilepsia*, **2020**, 61, 1793-1794	6.4	
175	Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. *Epilepsia*, **2020**, 61, 149-156	6.4	0
174	Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. *Epilepsia*, **2020**, 61, 2365-2385	6.4	18
173	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. *Clinical Pharmacokinetics*, **2020**, 59, 1493-1500	6.2	9
172	Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 1078-1082	5.6	6
171	Novel treatment approaches and pediatric research networks in status epilepticus. *Epilepsy and Behavior*, **2019**, 101, 106564	3.2	1
170	Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent-induced seizures in pediatric rats. *Epilepsia*, **2019**, 60, 315-321	6.4	5
169	Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. *Birth Defects Research*, **2019**, 111, 1013-1023	2.9	7
168	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. *Epilepsia*, **2018**, 59, 1811-1841	6.4	89

167	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. *Epilepsia*, **2018**, 59, 1842-1866	6.4	32
166	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). *Epilepsia*, **2017**, 58, 181-221	6.4	78
165	Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. *Molecular Diagnosis and Therapy*, **2017**, 21, 75-83	4.5	5
164	A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. *Bipolar Disorders*, **2017**, 19, 285-294	3.8	6
163	Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide. *Neurochemical Research*, **2017**, 42, 1972-1982	4.6	9
162	sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. *Pharmacological Research*, **2017**, 117, 129-139	10.2	9
161	Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	9
160	sec-Butylpropylacetamide (SPD) has antimigraine properties. *Cephalalgia*, **2016**, 36, 924-35	6.1	10
159	Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. *Molecular Pharmaceutics*, **2016**, 13, 2492-6	5.6	6
158	Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 4246-4253	3.4	5
157	Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid. *Epilepsy and Behavior*, **2015**, 46, 72-8	3.2	9
156	Third International Congress on Epilepsy, Brain and Mind: Part 1. *Epilepsy and Behavior*, **2015**, 50, 116-37	3.2	8
155	Eslicarbazepine Acetate **2015**, 447-459		
154	Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. *Bipolar Disorders*, **2015**, 17, 615-25	3.8	13
153	The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. *Epilepsy and Behavior*, **2015**, 49, 298-302	3.2	19
152	Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). *Epilepsy Research*, **2015**, 111, 85-141	3	143
151	Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations. *CNS Drugs*, **2014**, 28, 69-77	6.7	17
150	Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. *Epilepsia*, **2014**, 55, 353-61	6.4	23

149	Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. *Epilepsia*, **2014**, 55, 1944-52	6.4	8
148	sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. *Epilepsia*, **2014**, 55, 1953-8	6.4	17
147	Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. *Journal of Medicinal Chemistry*, **2013**, 56, 6467-77	8.3	17
146	Valproic acid derivatives signal for apoptosis and repair in vitro. *Clinical Biochemistry*, **2013**, 46, 1532-7	3.5	5
145	Quantitative assessment of the switchability of generic products. *European Journal of Pharmaceutical Sciences*, **2013**, 50, 476-83	5.1	12
144	Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice. *Birth Defects Research Part B: Developmental and Reproductive Toxicology*, **2013**, 98, 318-27		
143	Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. *Epilepsia*, **2013**, 54, 1453-61	6.4	31
142	Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. *Epilepsy Research*, **2013**, 106, 64-73	3	5
141	Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2013**, 1831, 880-6	5	4
140	Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). *Epilepsy Research*, **2013**, 103, 2-30	3	171
139	Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. *Epilepsia*, **2013**, 54 Suppl 6, 99-102	6.4	15
138	Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. *Epilepsia*, **2013**, 54, 1444-52	6.4	24
137	Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. *Epilepsy Research*, **2012**, 98, 238-46	3	6
136	Pharmacokinetics and drug interactions of eslicarbazepine acetate. *Epilepsia*, **2012**, 53, 935-46	6.4	119
135	Comments on the working group's 2012 review of the Program. *Epilepsia*, **2012**, 53, 1844-6	6.4	2
134	Why are antiepileptic drugs used for nonepileptic conditions?. *Epilepsia*, **2012**, 53 Suppl 7, 26-33	6.4	103
133	How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)?. *Epilepsia*, **2012**, 53 Suppl 8, 3-11	6.4	17
132	The borderland of epilepsy: Chairs' Symposium, 10th European Congress on Epileptology, London--October 1, 2012. Introduction. *Epilepsia*, **2012**, 53 Suppl 7, 1-2	6.4	1

131	Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. *Journal of Medicinal Chemistry*, **2012**, 55, 2835-45	8.3	19
130	Chemical properties of antiepileptic drugs (AEDs). *Advanced Drug Delivery Reviews*, **2012**, 64, 887-95	18.5	106
129	A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. *Epilepsia*, **2012**, 53, 134-46	6.4	54
128	The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. *DMM Disease Models and Mechanisms*, **2012**, 5, 115-24	4.1	50
127	Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. *Journal of Medicinal Chemistry*, **2011**, 54, 3977-81	8.3	65
126	Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid. *Epilepsy and Behavior*, **2011**, 22, 461-8	3.2	8
125	Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. *Epilepsia*, **2011**, 52, 1877-83	6.4	19
124	Key factors in the discovery and development of new antiepileptic drugs. *Nature Reviews Drug Discovery*, **2010**, 9, 68-82	64.1	360
123	Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. *Neuropharmacology*, **2010**, 58, 1228-36	5.5	25
122	Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. *Journal of Medicinal Chemistry* , **2010**, 53, 4177-86	8.3	21
121	Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. *Epilepsia*, **2010**, 51, 941-50	6.4	40
120	Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). *Epilepsy Research*, **2010**, 92, 89-124	3	122
119	Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. *Epilepsia*, **2010**, 51, 323-32	6.4	4
118	Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. *Epilepsia*, **2010**, 51, 1944-53	6.4	5
117	Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice. *Birth Defects Research Part B: Developmental and Reproductive Toxicology*, **2009**, 86, 394-401		3
116	Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. *Epilepsia*, **2009**, 50, 1850-9	6.4	4
115	Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus. *Epilepsia*, **2009**, 50 Suppl 12, 44-8	6.4	84
114	Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. *Journal of Medicinal Chemistry*, **2009**, 52, 7236-48	8.3	31

113	Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. *Journal of Medicinal Chemistry*, **2009**, 52, 2233-42	8.3	39
112	Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid. *Epilepsia*, **2008**, 49, 1202-12	6.4	14
111	Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. *Neuropharmacology*, **2008**, 54, 699-707	5.5	6
110	Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice. *Birth Defects Research Part A: Clinical and Molecular Teratology*, **2008**, 82, 610-21		4
109	Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6297-305	3.4	14
108	Extended-release formulations for the treatment of epilepsy. *CNS Drugs*, **2007**, 21, 765-74	6.7	52
107	Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. *Journal of Medicinal Chemistry*, **2007**, 50, 6419-27	8.3	43
106	Valproic Acid: second generation. *Neurotherapeutics*, **2007**, 4, 130-7	6.4	108
105	Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. *Epilepsy Research*, **2007**, 73, 75-84	3	6
104	Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. *Epilepsia*, **2007**, 48, 497-504	6.4	104
103	An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. *Epilepsia*, **2007**, 48, 1328-38	6.4	19
102	Generic products of antiepileptic drugs (AEDs): is it an issue?. *Epilepsia*, **2007**, 48, 1825-32	6.4	59
101	Clinical pharmacology of parenteral use of antiepileptic drugs. *Epilepsia*, **2007**, 48 Suppl 8, 46-8	6.4	6
100	Development of new antiepileptic drugs: challenges, incentives, and recent advances. *Lancet Neurology, The*, **2007**, 6, 793-804	24.1	259
99	Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. *Birth Defects Research Part B: Developmental and Reproductive Toxicology*, **2006**, 77, 227-33		7
98	New antiepileptic drugs that are second generation to existing antiepileptic drugs. *Expert Opinion on Investigational Drugs*, **2006**, 15, 637-47	5.9	85
97	Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug. *Neuropharmacology*, **2006**, 51, 933-46	5.5	16
96	Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. *Epilepsia*, **2006**, 47, 1822-9	6.4	35

95	Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. *Epilepsia*, **2006**, 47, 1830-40	6.4	25
94	Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. *Neuropharmacology*, **2005**, 49, 1110-20	5.5	28
93	The pharmacokinetics and interactions of new antiepileptic drugs: an overview. *Therapeutic Drug Monitoring*, **2005**, 27, 722-6	3.2	33
92	Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. *Epilepsy Research*, **2005**, 63, 103-12	3	80
91	A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. *Epilepsia*, **2005**, 46, 1046-54	6.4	21
90	Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. *British Journal of Pharmacology*, **2005**, 146, 198-208	8.6	48
89	Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. *Epilepsia*, **2005**, 46, 378-84	6.4	50
88	Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. *Biochemical Pharmacology*, **2005**, 69, 1501-8	6	41
87	Critical analysis of the discrepancy between V(beta) and V(ss) for drugs exhibiting different two-compartment disposition profiles. *Biopharmaceutics and Drug Disposition*, **2005**, 26, 51-8	1.7	3
86	Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. *Birth Defects Research Part A: Clinical and Molecular Teratology*, **2005**, 73, 229-38		39
85	Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. *Drug Metabolism and Disposition*, **2005**, 33, 1538-46	4	11
84	Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing model-independent approach. *Biopharmaceutics and Drug Disposition*, **2004**, 25, 99-101	1.7	2
83	The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model. *Biopharmaceutics and Drug Disposition*, **2004**, 25, 157-62	1.7	6
82	Polycomb homologs are involved in teratogenicity of valproic acid in mice. *Birth Defects Research Part A: Clinical and Molecular Teratology*, **2004**, 70, 870-9		12
81	Amidic modification of valproic acid reduces skeletal teratogenicity in mice. *Birth Defects Research Part B: Developmental and Reproductive Toxicology*, **2004**, 71, 47-53		25
80	Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. *Epilepsy Research*, **2004**, 58, 1-12	3	10
79	Valproate decreases inositol biosynthesis. *Biological Psychiatry*, **2004**, 56, 868-74	7.9	94
78	Pharmacokinetic interactions of topiramate. *Clinical Pharmacokinetics*, **2004**, 43, 763-80	6.2	124

77	Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. *Epilepsy and Behavior*, **2004**, 5, 866-72	3.2	54
76	Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. *Journal of Medicinal Chemistry*, **2004**, 47, 4316-26	8.3	34
75	Therapeutic drug monitoring of the newer antiepileptic drugs. *Therapeutic Drug Monitoring*, **2003**, 25, 347-63	3.2	245
74	Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. *Therapeutic Drug Monitoring*, **2003**, 25, 314-22	3.2	32
73	New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?. *Current Opinion in Neurology*, **2003**, 16, 203-211	7.1	59
72	Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. *Pharmaceutical Research*, **2003**, 20, 1293-301	4.5	32
71	Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2003**, 788, 125-36	3.2	1
70	Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. *Epilepsia*, **2003**, 44, 540-9	6.4	127
69	Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. *Epilepsia*, **2003**, 44, 917-22	6.4	44
68	Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. *British Journal of Pharmacology*, **2003**, 138, 602-13	8.6	21
67	Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. *British Journal of Pharmacology*, **2003**, 139, 755-64	8.6	13
66	New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?. *Current Opinion in Neurology*, **2003**, 16, 203-11	7.1	15
65	Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug. *Epilepsia*, **2002**, 43, 115-26	6.4	29
64	Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. *Epilepsia*, **2002**, 43, 691-6	6.4	59
63	New antiepileptic drugs currently in clinical trials: is there a strategy in their development?. *Therapeutic Drug Monitoring*, **2002**, 24, 85-90	3.2	18
62	Pros and cons for the development of new antiepileptic drugs. *CNS Drugs*, **2002**, 16, 285-9	6.7	9
61	Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. *Epilepsia*, **2001**, 42, 831-6	6.4	30
60	Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system--active chiral valproylamide. *Therapeutic Drug Monitoring*, **2001**, 23, 414-20	3.2	4

59	Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. *Therapeutic Drug Monitoring*, **2000**, 22, 574-81	3.2	6
58	Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. *Epilepsia*, **2000**, 41, 1107-11	6.4	9
57	In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy. *Pharmaceutical Research*, **2000**, 17, 1408-13	4.5	23
56	Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. *Pharmaceutical Research*, **2000**, 17, 216-21	4.5	11
55	Absolute configuration of the four stereoisomers of valnoctamide (2-ethyl-3-methyl valeramide), a potentially new stereospecific antiepileptic and CNS drug. *Tetrahedron: Asymmetry*, **1999**, 10, 841-853		15
54	Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. *Epilepsia*, **1999**, 40, 545-52	6.4	4
53	Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. *Pharmaceutical Research*, **1999**, 16, 1582-8	4.5	23
52	Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. *Clinical Pharmacology and Therapeutics*, **1999**, 66, 547-53	6.1	60
51	Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. *Journal of Controlled Release*, **1999**, 62, 187-92	11.7	20
50	Use of mean residence time to determine the magnitude of difference between rate constants and to calculate tmax in the Bateman equation. *Biopharmaceutics and Drug Disposition*, **1999**, 20, 3-9	1.7	1
49	Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. *Chirality*, **1999**, 11, 645-50	2.1	13
48	Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. *Epilepsia*, **1998**, 39, 513-9	6.4	18
47	Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. *European Journal of Pharmaceutical Sciences*, **1998**, 6, 93-8	5.1	11
46	Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. *Epilepsy Research*, **1998**, 30, 41-8	3	50
45	The disposition of valproyl glycinamide and valproyl glycine in rats. *Pharmaceutical Research*, **1997**, 14, 873-8	4.5	13
44	Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. *Biopharmaceutics and Drug Disposition*, **1997**, 18, 557-66	1.7	9
43	Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. *Clinical Pharmacology and Therapeutics*, **1997**, 61, 442-9	6.1	36
42	The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. *Clinical Pharmacokinetics*, **1996**, 31, 29-46	6.2	107

41	Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide. *Pharmaceutical Research*, **1996**, 13, 284-9	4.5	24
40	Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. *Biopharmaceutics and Drug Disposition*, **1996**, 17, 565-75	1.7	4
39	Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. *Pharmaceutical Research*, **1995**, 12, 905-10	4.5	26
38	Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. *Journal of Pharmaceutical Sciences*, **1995**, 84, 1160-3	3.9	6
37	Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. *Biopharmaceutics and Drug Disposition*, **1995**, 16, 201-10	1.7	14
36	Can we develop improved derivatives of valproic acid?. *International Journal of Clinical Pharmacy*, **1994**, 16, 2-6		32
35	Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment. *Biopharmaceutics and Drug Disposition*, **1994**, 15, 45-52	1.7	4
34	Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs. *Biopharmaceutics and Drug Disposition*, **1994**, 15, 609-16	1.7	2
33	Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. *Pharmaceutical Research*, **1994**, 11, 1429-34	4.5	13
32	Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. *Clinical Pharmacology and Therapeutics*, **1994**, 56, 471-6	6.1	82
31	Comparative pharmacokinetics of the newer antiepileptic drugs. *Clinical Pharmacokinetics*, **1993**, 24, 441-52	6.2	77
30	Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid. *Biopharmaceutics and Drug Disposition*, **1993**, 14, 51-9	1.7	3
29	Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. *Pharmaceutical Research*, **1993**, 10, 703-8	4.5	173
28	Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. *Clinical Pharmacokinetics*, **1992**, 22, 11-21	6.2	26
27	Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide. *Pharmaceutical Research*, **1992**, 9, 1058-63	4.5	16
26	The effect of raising gastric pH with ranitidine on the absorption and elimination of theophylline from a sustained-release theophylline tablet. *Pharmaceutical Research*, **1991**, 8, 1516-9	4.5	6
25	Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid. *Pharmaceutical Research*, **1991**, 8, 750-3	4.5	13
24	Stability of diltiazem in different biological fluids. *Biopharmaceutics and Drug Disposition*, **1991**, 12, 327-34	1.7	11

23	Clinical pharmacology of valpromide. *Clinical Pharmacokinetics*, **1991**, 20, 114-22	6.2	64
22	Pharmacokinetics of urinary metabolites of cannabidiol in the dog. *Biopharmaceutics and Drug Disposition*, **1990**, 11, 785-95	1.7	11
21	Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. *Journal of Pharmaceutical Sciences*, **1990**, 79, 719-24	3.9	31
20	Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. *Pharmaceutical Research*, **1989**, 6, 683-9	4.5	45
19	The logical structure and validity of experimental designs in pharmacokinetics and clinical pharmacology. *Biopharmaceutics and Drug Disposition*, **1989**, 10, 331-51	1.7	
18	Pharmacokinetic interaction between diltiazem and amiodarone in the dog. *Biopharmaceutics and Drug Disposition*, **1989**, 10, 423-9	1.7	3
17	Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. *Journal of Pharmaceutical Sciences* , **1988**, 77, 831-4	3.9	18
16	In vitro protein binding interaction studies involving cefixime. *Biopharmaceutics and Drug Disposition*, **1988**, 9, 315-20	1.7	4
15	Pharmacokinetics of T-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, T-2 toxin, in dog. *Xenobiotica*, **1987**, 17, 941-50	2	9
14	Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. *Biopharmaceutics and Drug Disposition*, **1987**, 8, 427-35	1.7	7
13	Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog. *Pharmaceutical Research*, **1987**, 4, 33-7	4.5	4
12	Pharmacokinetic/Pharmacodynamic Basis of Controlled Drug Delivery. *Drugs and the Pharmaceutical Sciences*, **1987**, 213-251		9
11	Relation between absorption half-life values of four novel sustained-release dosage forms of valproic acid in dogs and humans. *Biopharmaceutics and Drug Disposition*, **1986**, 7, 495-500	1.7	6
10	The relationship between drug input and mean residence time in the body. *Biopharmaceutics and Drug Disposition*, **1986**, 7, 577-83	1.7	5
9	Pharmacokinetics of valproic acid in volunteers after a single dose study. *Biopharmaceutics and Drug Disposition*, **1985**, 6, 33-42	1.7	13
8	Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. *Biopharmaceutics and Drug Disposition*, **1985**, 6, 401-11	1.7	20
7	Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. *Biopharmaceutics and Drug Disposition*, **1984**, 5, 1-10	1.7	11
6	Pharmacokinetics of valpromide in dogs after various modes of administration. *Biopharmaceutics and Drug Disposition*, **1984**, 5, 177-83	1.7	15

5	A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs. *Journal of Pharmacy and Pharmacology*, **1983**, 35, 607-9	4.8	14
4	Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. *Biopharmaceutics and Drug Disposition*, **1982**, 3, 129-64	1.7	12
3	An alternative method for calculating simple pharmacokinetic parameters for zero-order absorption and first-order elimination processes. *Biopharmaceutics and Drug Disposition*, **1981**, 2, 323-7	1.7	1
2	Structure elucidation of a condensation product of 4-aminopyrrole derivatives and dicyclohexylcarbodiimide. *Journal of Heterocyclic Chemistry*, **1980**, 17, 1797-1798	1.9	4
1	Eslicarbazepine Acetate485-498		29